This page shows the latest Juluca news and features for those working in and with pharma, biotech and healthcare.
There was an acceleration in sales of ViiV’s new two-drug combinations Juluca (dolutegravir/rilpivirine) and Dovato (dolutegravir/lamivudine) however, which GSK sees as the main weapon in its arsenal
That is a concern which some suggest has been behind the relatively slow take-up of Juluca since its launch. ... For comparison, Biktarvy brought in $739m in sales in the first quarter of the year, compared to $70m for Juluca in the second-line setting.
Dovato is the second two-drug combination to be introduced by the company after Juluca (dolutegravir/rilpivirine), which is approved for use in patients a second-line option for patients who ... Juluca struggled to make much headway with sales running at
GSK is looking to a series of new two-drug HIV drugs to inject new momentum in the HIV franchise, and the first of these – Juluca (dolutegravir/rilpivirine) – added £70m in ... ViiV chairman David Redfern said Juluca and Dovato – alongside
ViiV already have another two-in-one STR, Juluca (dolutegravir/rilpivirine), but this is only approved for HIV patients who have achieved viral suppression with another antiretroviral therapy. ... Recent studies have set Juluca up to be a strong
Gilead’s new drug is facing competition from GSK’s new arrival in HIV, Juluca.
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Established in 2001, Fishawack Health (FH) is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries....